A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings. The new ...
MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...
The management of PI underwent a transformative shift in 1979 with the US Food and Drug Administration (FDA) approval of intravenous immunoglobulin (IVIg), which became the standard therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback